XML 26 R11.htm IDEA: XBRL DOCUMENT v3.3.1.900
Investments (Notes)
 12 Months Ended
Jan. 02, 2016
Investments [Abstract]  
Investments
Investments

Marketable Debt Securities

Investments in marketable debt securities were comprised of the following (in thousands):
 
January 2, 2016
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Fair
Value
Corporate bonds
$
7,532

 
$
—

 
$
(19
)
 
$
7,513

Municipal bonds
5,114

 
—

 
(3
)
 
5,111

U.S. Agency bonds
2,497

 
—

 
(1
)
 
2,496

 
$
15,143

 
$
—

 
$
(23
)
 
$
15,120

 
January 3, 2015
 
Amortized
Cost
 
Unrealized
Gains
 
Unrealized
Losses
 
Fair
Value
U.S. Treasury securities
$
32,507

 
$
12

 
$
(23
)
 
$
32,496

Corporate bonds
35,409

 
2

 
(36
)
 
35,375

U.S. Agency bonds
22,545

 
4

 
(10
)
 
22,539

Municipal bonds
11,157

 
2

 
(5
)
 
11,154

Commercial paper
12,487

 
—

 
(1
)
 
12,486

 
$
114,105

 
$
20

 
$
(75
)
 
$
114,050



Maturities of marketable debt securities were as follows (in thousands):
 
January 2, 2016
 
January 3, 2015
 
Amortized
Cost
 
Fair
Value
 
Amortized
Cost
 
Fair
Value
Marketable debt securities – current (due in less than one year)
$
6,575

 
$
6,567

 
$
69,607

 
$
69,609

Marketable debt securities – non-current (due in one to two years)
8,568

 
8,553

 
44,498

 
44,441

 
$
15,143

 
$
15,120

 
$
114,105

 
$
114,050


During 2015, 2014 and 2013, respectively, we received proceeds of $127.5 million, $54.2 million and $53.3 million, respectively, from marketable debt securities.

Other Investments

We previously held a minority equity investment in one of our strategic product-development partners, BAM Labs, Inc. In September 2015, we completed the acquisition of the remaining outstanding capital stock of BAM Labs, Inc. The carrying value of our equity investment in BAM Labs, Inc. prior to the acquisition was $6.0 million based on the cost method. In connection with the acquisition, our equity investment was remeasured to a fair value of $12.9 million, resulting in a $3.5 million gain net of expenses, including $3.4 million of acquisition-related expenses. The remeasured fair value of our equity investment was based on the fair value of BAM Labs, Inc. at the acquisition date. The net gain of $3.5 million is included in general and administrative expenses on our consolidated statement of operations for the fiscal year ended January 2, 2016. See Note 2, Acquisition of BAM Labs, Inc., for details regarding this acquisition.